A Multicenter, Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled Study to Investigate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs GSK 2982772 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 05 Oct 2017 Planned number of patients changed from 36 to 32.
- 06 Jul 2017 Planned End Date changed from 13 Apr 2018 to 17 Sep 2018.
- 06 Jul 2017 Planned primary completion date changed from 1 Apr 2018 to 17 Sep 2018.